Cancer Immunotherapy News and Research

RSS

Stand Up To Cancer announces $1.1 million in funding to foster collaborative research

Stand Up To Cancer announced today five new awards that will cut across institutional and national lines to foster collaborative research and explore new paths to improve cancer treatment.

29 Jul 2020

Hollings Cancer Center researcher receives NCI grants for cancer immunotherapy studies

Hollings Cancer Center researcher Jessica Thaxton, Ph.D., is the recipient of two grants totaling $3.4 million from the National Cancer Institute for her work in cancer immunotherapy and cell stress, one of which is part of the Cancer Moonshot Initiative on immunometabolism.

23 Jul 2020

Research could lead to more efficient cellular immunotherapies for advanced cancers

Adoptive cell transfer immunotherapy is one of the most promising new treatments for people with hard-to-treat cancers.

23 Jul 2020

Immunotherapy does not worsen complications for patients with both COVID-19 and cancer

Preliminary data from researchers at the University of Cincinnati Cancer Center show that immunotherapy doesn't necessarily worsen complications for patients with both COVID-19 and cancer.

20 Jul 2020

Common antioxidant enzyme catalase as COVID-19 treatment

A new paper by researchers from the USA and China and published on the preprint server bioRxiv in July 2020 discusses a new drug based on the catalase enzyme, which could play a vital part in reducing the inflammation associated with progressive and severe COVID-19 disease.

17 Jul 2020

NCI funds researchers to investigate how antibody responses affect COVID-19 outcomes

A $328,000 National Cancer Institute grant will enable researchers at Dartmouth's and Dartmouth-Hitchcock's Norris Cotton Cancer Center (NCCC) to investigate one of the mechanisms that may be responsible for the body's inability to fight COVID-19.

16 Jul 2020

Biological anti-tumor mechanism can provide long-term immune response against tumors

Blocking a newly identified "immune memory checkpoint" in immune cells could improve immunotherapy and help prevent cancers from recurring, according to new findings in mice and human samples by researchers at the UPMC Hillman Cancer Center and the University of Pittsburgh School of Medicine.

15 Jul 2020

Two new studies highlight possible treatment options for patients with neuroendocrine tumors

Two new studies led by Renuka Iyer, MD, Section Chief for Gastrointestinal Oncology at Roswell Park Comprehensive Cancer Center, highlight possible new treatment options for patients with neuroendocrine tumors (NETs) - a rare and hard-to-treat cancer.

14 Jul 2020

Breast cancer cells can reprogram natural killer cells to aid in metastasis

Natural killer cells, a type of immune cell, are known to limit metastasis by inducing the death of cancer cells. But metastases still form in patients, so there must be ways for cancer cells to escape.

9 Jul 2020

Salk Institute expands research to find treatments and cures for COVID-19

As the COVID-19 pandemic continues across the globe, the Salk Institute joins in efforts to understand the fundamental science behind the novel coronavirus to pave the way to treatments and cures.

30 Jun 2020

Noile-Immune Biotech and C4U team up to develop CRISPR/Cas3 technology

Noile-Immune Biotech Inc., ("Noile-Immune") and C4U Corporation, ("C4U") announced that they have entered into an agreement on joint research and commercialization of next-generation allogeneic gene-modified immune cell therapy combining C4U's CRISPR/Cas3 genome editing technology and Noile-Immune's PRIME (Proliferation inducing and migration enhancing) technology designed to improve proliferation and trafficking of immune cells into solid tumors.

27 Jun 2020

A new approach to track down cryptic peptides

Almost all cells of the human body present fragments of cellular proteins on their surface, so-called human leukocyte antigens or HLA peptides, which play an important role in the immune response.

23 Jun 2020

Manipulating macrophages could be a viable strategy for treating cancer

Most traditional cancer therapies target either the tumor cells themselves or indiscriminately kill any rapidly dividing cell.

22 Jun 2020

Novel immunotherapy-plus-chemotherapy combo for pleural mesothelioma shows promise

Inoperable malignant pleural mesothelioma, is a rare and aggressive cancer of the protective lining of the lungs, or pleura, often caused by exposure to asbestos.

11 Jun 2020

Turning autoimmunity drugs into anti-cancer treatments

Professor Mark Cragg speaks to News-Medical about his research which involves turning autoimmunity drugs into anti-cancer treatments.

11 Jun 2020

Immuno-oncology may accelerate the development of treatments for COVID-19

Researchers at Roswell Park Comprehensive Cancer Center have been actively engaged in the effort to develop treatments or other control strategies that can help communities worldwide to address the impacts of the COVID-19 pandemic.

10 Jun 2020

Scientists harness cancer immunotherapy tools to identify targets for COVID-19 vaccine

Cancer researchers at Children's Hospital of Philadelphia have harnessed tools used for the development of cancer immunotherapies and adapted them to identify regions of the SARS-CoV-2 virus to target with a vaccine, employing the same approach used to elicit an immune response against cancer cells to stimulate an immune response against the virus.

8 Jun 2020

Tumors cause disruption of the immune system throughout the body, study finds

Cancer treatment has advanced with the advent of immunotherapies that, in some cancers, can overcome tumors' ability to evade the immune system by suppressing local immune responses.

3 Jun 2020

Phase III clinical trial shows benefit of rituximab for pediatric Burkitt lymphoma

Results of the phase III Inter-B-NHL-ritux 2010 clinical trial reported today in the New England Journal of Medicine show 95 percent three-year survival for pediatric patients with advanced B-cell non-Hodgkin lymphoma treated with the addition of anti-cancer immunotherapy rituximab to standard chemotherapy.